Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client, Targacept, Inc. in the company’s public offering of its common stock. The offering, in which the company raised $45 million in proceeds, was underwritten by Deutsche Bank Securities.
Winston-Salem, North Carolina-based Targacept, Inc. is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders.
Targacept was represented by Megan Gates and Jonathan Kravetz, Members and Co-Chairs of Mintz Levin’s Securities Practice. Also assisting in the transaction were Linda Bentley, a Member in the firm’s Corporate and Life Sciences Practices, and Joel Papernik, a Member in Mintz Levin’s Corporate Practice.
Mintz Levin is an international law firm representing the life science industry since its inception, and today has one of the largest life science practices in the United States. Since 2004, the firm’s life sciences practice has completed over 340 transactions including: mergers and acquisitions totaling over $7 billion; venture capital deals totaling over $1 billion; more than 50 public offerings totaling over $5.2 billion; numerous strategic collaborations valued at over $2.5 billion and dozens of other financings.
Contacts:
Mintz Levin
Gina Addis, 617-348-4413
gaddis@mintz.com
